Understanding the role of DNMT1 SUMOylation in Acute Myeloid Leukaemia

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/2003909

Funding Status
Status not available

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

Most cancers have abnormally high levels of DNA methylation, which turns off cell death genes, making cancer cells immortal. We have a new drug, called DNMT1i, that targets this feature of cancer cells and we recently found a new drug target that enhances the activity of DNMT1i. Our research will determine how these two drugs synergise to effectively kill cancer cells and will justify their use in clinical trials, which we believe will improve outcomes for patients with cancer.

Funded Activity Details

Start Date: 01-01-2020

End Date: End date not available

Funding Scheme: Ideas Grants

Funding Amount: $639,290.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

anticancer drug action | dna methylation | epigenetics | ubiquitin-mediated proteolysis

Related Links